Inflammation and heart disease in men: What to test and what to do next

Chronic, low-grade inflammation is a proven risk factor for atherosclerotic heart disease, and simple blood tests can detect it before symptoms appear. If your cholesterol looks “fine” but your family history, waistline, or energy say otherwise, inflammation may be the missing piece in your heart risk assessment.

Key takeaways

• Inflammatory risk-enhancing factors (including high-sensitivity C-reactive protein) can refine ASCVD risk assessment beyond a standard lipid panel in selected men. ^[2]
• When measured away from acute illness, hsCRP <1 mg/L suggests lower risk, 1–3 mg/L suggests average risk, and >3 mg/L suggests higher risk; confirm persistence with repeat testing. ^[3]
• Lipoprotein(a) is largely genetic, and an Lp(a) level ≥50 mg/dL (or ≥125 nmol/L) is a risk-enhancing factor; many men only need it checked once unless treatment decisions change. ^[2]
• A higher triglyceride-to-HDL cholesterol ratio often travels with insulin resistance and visceral fat, which commonly overlap with chronic inflammation and higher cardiometabolic risk.
• Marine omega-3s (EPA+DHA) have clinical-trial evidence for modestly lowering CRP in some populations, and curcumin has human evidence for lowering inflammatory markers in some settings; use them to support (not replace) lifestyle changes and guideline-based care. ^[13],[14]

Why inflammation is a heart disease risk factor for men

Chronic low-grade inflammation increases atherosclerotic cardiovascular disease (ASCVD) risk in men by promoting endothelial dysfunction, plaque growth, and plaque instability. ASCVD is heart and vascular disease caused by plaque buildup that narrows and stiffens arteries. ^[1]

Most men learn their “heart numbers” from a lipid panel. That panel is useful, but it cannot fully explain who develops heart disease or why. Modern prevention guidance recognizes that certain inflammatory and metabolic signals can clarify “residual” or underrecognized risk, especially when traditional cholesterol targets look acceptable on paper. ^[2]

There is another problem: chronic inflammation often feels like nothing. Men may chalk subtle changes up to work stress, aging, or poor sleep. That is why selective inflammation testing can be valuable. It can identify risk earlier, when lifestyle changes and clinician-guided care can still slow the process. ^[3]

How inflammation drives plaque and heart attacks

Inflammation injures the endothelium

One major pathway linking inflammation to ASCVD is endothelial dysfunction. ^[1] The endothelium is the inner lining of blood vessels. When it is irritated by chronic immune signaling, vessels become stiffer and less able to regulate blood flow and vascular tone. ^[1]

This matters for men because blood vessels are the “delivery system” not just for the heart, but also for exercise performance and sexual function. You can be strong in the gym and still have early vascular damage if inflammation stays high for years.

Inflammation helps plaque form and then makes it unstable

Atherosclerosis is not only a “cholesterol storage” problem. It is also an immune problem. Plaque is a fatty, fibrous buildup in the artery wall. Inflamed vessel walls are more likely to form plaque, and inflammation can make existing plaque more likely to rupture. ^[1]

Plaque rupture is a key trigger for major events. When a plaque breaks open, the body treats it like an injury and tries to patch it. That patch can become a clot that blocks blood flow, causing a heart attack or stroke. ^[1]

Inflammation raises clot tendency

Chronic inflammation shifts the body toward a more prothrombotic state, meaning a higher tendency to form clots. ^[1] That is one reason inflammation is connected to both heart attack and ischemic stroke risk.

In practice, this is why two men with the same LDL cholesterol can have very different outcomes. If one has persistent inflammatory activation, his arteries and blood chemistry behave differently under stress.

Why “ratios” can beat single lab numbers

Looking at one biomarker in isolation can miss patterns that matter for inflammation and ASCVD risk. For lipids, apolipoprotein B (ApoB) can be a helpful add-on because it reflects the number of atherogenic lipoprotein particles, and it is listed as a risk-enhancing factor when elevated. ^[2]

Some clinicians also look at LDL cholesterol relative to ApoB as a rough clue to LDL particle characteristics. A lower LDL-to-ApoB ratio can be consistent with a higher proportion of smaller, denser LDL particles, which are more likely to penetrate artery walls and contribute to atherosclerosis. ^[5]

Another practical ratio is triglycerides divided by HDL cholesterol. This ratio is commonly used as a rough proxy for insulin resistance and cardiometabolic risk (especially alongside waist circumference, blood pressure, and fasting glucose), which often overlaps with chronic inflammation.

What fuels chronic inflammation in men

Chronic inflammation rarely has one cause. It is usually a stack of inputs that keep the immune system slightly activated for years. When you are trying to reduce inflammation heart disease risk, the goal is to find the biggest drivers you can actually change.

• Visceral fat and insulin resistance. Visceral fat is fat stored around internal organs. It releases pro-inflammatory signals that worsen insulin resistance, and these processes can reinforce one another in a cycle that raises cardiometabolic risk. ^[6]
• Smoking. Cigarette smoke increases oxidative stress and vascular injury, which amplifies inflammatory signaling and atherosclerosis progression. ^[10]
• Poor sleep. Ongoing sleep disruption is associated with higher blood pressure, impaired glucose control, and inflammatory activation over time. In practice, sleep is a high-leverage target because it affects appetite, training recovery, and stress resilience.
• Chronic stress. Chronic stress is linked to sustained immune activation and higher inflammatory signaling in many contexts, which can compound cardiometabolic risk. ^[9]
• Autoimmune and inflammatory diseases. These conditions keep the immune system “on” even when there is no infection, and they can raise long-term vascular risk through persistent inflammation. ^[11]

Limitations note: These links are real, but they are not a perfect checklist. Inflammation biomarkers such as hsCRP are sensitive, not specific. A high result can reflect gum disease, an intense new training block, or a recent infection, not just heart disease risk. Context matters, and repeat testing is often necessary. ^[3]

Signs and lab signals to watch

Most men with chronic inflammation do not feel “inflamed.” That is what makes it dangerous. Instead of pain, you may notice vague performance issues and slow drift in health markers.

• Everyday signals that should raise suspicion: persistent low energy, reduced training recovery, rising waist circumference, higher fasting triglycerides, higher blood pressure, or brain fog that does not match your lifestyle habits.
• Situations where inflammation testing is especially worth it: family history of early heart disease, normal LDL cholesterol with abnormal triglycerides, or cardiovascular events despite being on standard therapy.

High-sensitivity C-reactive protein (hsCRP) is the most validated blood test for low-grade inflammation in cardiovascular risk screening. CRP is made by the liver in response to inflammation, and high-sensitivity testing can detect smaller increases that routine CRP may miss. ^[3]

• <1.0 mg/L: lower risk ^[3]
• 1.0 to 3.0 mg/L: average risk ^[3]
• >3.0 mg/L: higher risk when persistent ^[3]

Do not test hsCRP right after an infection, injury, surgery, or a hard new exercise program. If hsCRP is elevated, repeat the test (often about two weeks later) when you are back at baseline to confirm that the elevation is persistent. ^[3]

Lipoprotein(a) is an inherited LDL-like particle associated with atherosclerotic risk. Prevention guidance recognizes Lp(a) ≥50 mg/dL (or ≥125 nmol/L) as a risk-enhancing factor, and levels are typically stable across adulthood. ^[2]

Remnant cholesterol refers to cholesterol carried in triglyceride-rich lipoproteins (such as VLDL remnants). Higher remnant cholesterol is associated with higher ischemic heart disease risk, and genetic and epidemiologic data support a causal role. ^[4]

You can estimate remnant cholesterol with a standard lipid panel: total cholesterol minus LDL cholesterol minus HDL cholesterol equals remnant cholesterol.

White blood cell patterns and RDW can add context. A complete blood count (CBC) with differential breaks down immune cell types, and RDW (red blood cell distribution width) reflects variation in red blood cell size that is associated with chronic inflammation and worse outcomes in many settings. ^[7],[8] Some clinicians also look at ratios from the CBC (such as neutrophils relative to lymphocytes) as a general inflammation signal, but cutoffs are not standardized and results should be interpreted in context.

What to do about inflammation and heart disease risk

Lowering inflammation heart disease risk is not about chasing one supplement or one number. It is about building a plan that starts with testing, then targets the biggest drivers, then retests to prove the plan is working.

1. Test the right markers, at the right time: Ask your clinician for a lipid panel plus hsCRP, triglycerides, HDL cholesterol, and lipoprotein(a). Consider ApoB and a CBC with differential if you and your clinician want a broader risk picture. If you also have symptoms that suggest hypogonadism (such as consistently low libido, erectile dysfunction, infertility concerns, or unexplained fatigue), discuss morning total testosterone testing on two separate days, using your lab’s reference range; many guidelines use total testosterone around 300 ng/dL (10.4 nmol/L) plus symptoms as a common diagnostic anchor, with free testosterone considered when SHBG is abnormal or results are borderline. ^[12]
2. Build the anti-inflammatory base layer first: Guideline-based prevention starts with consistent physical activity, weight management (especially reducing visceral fat), sleep prioritization, and a minimally processed eating pattern. ^[2] If smoking is in the mix, treat quitting as a medical priority because smoking-related oxidative stress is a direct inflammation amplifier. ^[10]
3. Escalate thoughtfully with a clinician, then monitor: If risk remains high after lifestyle work, your clinician may discuss medications that lower ASCVD risk (such as statins), and in selected patients statin therapy has shown benefit in people with elevated hsCRP even when LDL cholesterol is not markedly elevated. ^[15] If testing confirms testosterone deficiency with consistent symptoms, treatment decisions should be individualized, monitored (including hematocrit), and not pursued solely as a cardiovascular risk-reduction strategy; men who want to preserve fertility should involve a specialist because some approaches that stimulate endogenous testosterone may be considered off-label in select cases. ^[12]

Testosterone and cardiovascular risk: why it is sometimes part of the discussion

Testosterone is not an “inflammation marker,” but symptoms plus a consistently low testosterone level can coexist with visceral fat gain, insulin resistance, and reduced exercise capacity, which can indirectly worsen cardiometabolic risk in some men. Testing is most useful when it changes a broader plan (sleep, weight, alcohol intake, medication review, and targeted evaluation for reversible causes).

It is also important to separate diagnosis from treatment. Testosterone therapy can help appropriately selected men with confirmed hypogonadism, but it requires monitoring and shared decision-making. It should be guided by established clinical criteria, not by a single cutoff or a one-time lab result. ^[12]

Targeted supplements: Supplements can be useful adjuncts when your clinician agrees they fit your labs, medications, and goals. A meta-analysis of randomized trials found marine-derived omega-3 fatty acids were associated with reductions in CRP in some populations, with commonly used daily doses in the 2 to 4 gram range of EPA and DHA combined. ^[13] Curcumin has human evidence for improving some inflammatory markers in select settings, but product quality and absorption vary, and it should be treated as an add-on rather than a primary prevention strategy. ^[14]

Myth vs fact

Heart risk in men is rarely explained by one number. Lipids matter, but inflammation and metabolic health can change the story, especially when there is a strong family history, central weight gain, or early vascular disease.

Use “myth vs fact” as a way to sanity-check your assumptions before you overreact to a single lab value or overcommit to a single tool (like supplements) while ignoring basics that move multiple risk pathways at once.

• Myth:
  “If my LDL cholesterol is normal, I do not need to think about inflammation and heart disease.”
  Fact: Risk-enhancing factors (including hsCRP and certain inflammatory conditions) can clarify risk even when standard lipid goals look acceptable, which is why they are included in modern prevention frameworks. ^[2]
• Myth:
  “High-sensitivity C-reactive protein tells me exactly where inflammation is coming from.”
  Fact: hsCRP is sensitive but not specific. A high value can reflect infection, injury, or chronic disease. Confirm persistence and interpret it with your full clinical picture. ^[3]
• Myth:
  “I can take an anti-inflammatory supplement and skip lifestyle changes.”
  Fact: Human trials support some supplement effects on CRP, but prevention still starts with exercise, weight management, sleep, and diet quality. ^[2],[13]
• Myth:
  “Lipoprotein(a) is just another cholesterol number that will change if I eat better.”
  Fact: Lipoprotein(a) is largely genetic. It is mainly a risk clarifier, not a lifestyle scorecard, so many men only need to test it once. ^[2]

Bottom line

Inflammation heart disease risk is measurable and modifiable, but only if you look beyond the standard lipid panel. For many men, adding hsCRP, lipoprotein(a), ApoB-aware lipid interpretation, and metabolic markers helps explain risk that cholesterol alone misses. Start with repeatable lifestyle basics, then use clinician-guided medication and targeted adjuncts when lab patterns stay elevated.

References

1. Libby P. Inflammation in atherosclerosis. Nature. ;420:868-74. PMID: 12490960
2. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140:e596-e646. PMID: 30879355
3. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499-511. PMID: 12551878
4. Varbo A, Benn M, Tybjærg-Hansen A, et al. Remnant cholesterol as a causal risk factor for ischemic heart disease. Journal of the American College of Cardiology. 2013;61:427-436. PMID: 23265341
5. Berneis KK, Krauss RM. Metabolic origins and clinical significance of LDL heterogeneity. Journal of lipid research. 2002;43:1363-79. PMID: 12235168
6. de Luca C, Olefsky JM. Inflammation and insulin resistance. FEBS letters. 2008;582:97-105. PMID: 18053812
7. Riley LK, Rupert J. Evaluation of Patients with Leukocytosis. American family physician. 2015;92:1004-11. PMID: 26760415
8. May JE, Marques MB, Reddy VVB, et al. Three neglected numbers in the CBC: The RDW, MPV, and NRBC count. Cleveland Clinic journal of medicine. 2019;86:167-172. PMID: 30849034
9. Slavich GM, Irwin MR. From stress to inflammation and major depressive disorder: a social signal transduction theory of depression. Psychological bulletin. 2014;140:774-815. PMID: 24417575
10. Csordas A, Bernhard D. The biology behind the atherothrombotic effects of cigarette smoke. Nature reviews. Cardiology. 2013;10:219-30. PMID: 23380975
11. Firestein GS, McInnes IB. Immunopathogenesis of Rheumatoid Arthritis. Immunity. 2017;46:183-196. PMID: 28228278
12. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. The Journal of clinical endocrinology and metabolism. 2018;103:1715-1744. PMID: 29562364
13. Li K, Huang T, Zheng J, et al. Effect of marine-derived n-3 polyunsaturated fatty acids on C-reactive protein, interleukin 6 and tumor necrosis factor α: a meta-analysis. PloS one. 2014;9:e88103. PMID: 24505395
14. Hewlings SJ, Kalman DS. Curcumin: A Review of Its Effects on Human Health. Foods (Basel, Switzerland). 2017;6. PMID: 29065496
15. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. The New England journal of medicine. 2008;359:2195-207. PMID: 18997196